Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026
Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026
Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026
Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Deals

Andon Health to Fully Control iHealth by Acquiring Best Ventures’ Stake

Fineline Cube Feb 13, 2025

China-based Andon Health Co., Ltd (SHE: 002432) announced a plan to obtain the 20% stake...

Company

Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role

Fineline Cube Feb 13, 2025

Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co.,...

Company Drug

Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease

Fineline Cube Feb 13, 2025

Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...

Company

J&J Innovative Medicine China Appoints New General Manager and Oncology VP

Fineline Cube Feb 13, 2025

Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments...

Company Deals

Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder

Fineline Cube Feb 13, 2025

China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual...

Company Drug

Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU

Fineline Cube Feb 13, 2025

Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for...

Company Drug

Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA

Fineline Cube Feb 13, 2025

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products...

Company Deals

Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform

Fineline Cube Feb 13, 2025

US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm...

Company Medical Device

Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval

Fineline Cube Feb 13, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the...

Company Deals

Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer

Fineline Cube Feb 12, 2025

Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage...

Company Deals Drug

Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases

Fineline Cube Feb 12, 2025

Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc....

Company

Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology

Fineline Cube Feb 12, 2025

Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for...

Company Drug

Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study

Fineline Cube Feb 12, 2025

Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...

Company Drug

Hainan Poly Pharm’s Generic ProHance Wins FDA Approval in US

Fineline Cube Feb 12, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced that the US Food and Drug...

Company Deals

Kexing Biopharm and Bio-Thera Solutions Form Alliance for Global Expansion

Fineline Cube Feb 12, 2025

China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic...

Company Medical Device

MicroPort MedBot’s Toumai Surgical Robot Wins NMPA Approval for Single-Hole Laparoscopy

Fineline Cube Feb 12, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that the National Medical Products Administration...

Company Deals

Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio

Fineline Cube Feb 11, 2025

Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...

Company Drug

J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China

Fineline Cube Feb 11, 2025

US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...

Company Drug

Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials

Fineline Cube Feb 11, 2025

China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...

Company Deals

Roche Transfers InterMune and Esbriet to Legacy Pharma in IP Deal

Fineline Cube Feb 11, 2025

Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8...

Posts pagination

1 … 254 255 256 … 706

Recent updates

  • China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion
  • Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System
  • Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
  • Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend
  • Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.